Business Wire

MD-PREVAILION

19.10.2020 13:02:07 CEST | Business Wire | Press release

Share
Prevailion Named a 2020 Gartner “Cool Vendor” in Security Operations and Threat Intelligence Field

Prevailion, a global leader in cyber adversary intelligence, today announced that it has been recognized as a Gartner Cool Vendor in the latest Cool Vendors in Security Operations and Threat Intelligence report.

The Gartner report profiles “emerging vendors that security and risk management leaders should consider when evaluating emerging threats requiring the latest in security operations technologies.” Gartner writes that: “Security and risk management leaders are seeking solutions for better visibility into their IT environments to help strengthen their security posture, as well as prioritize security control gaps and remediation activities based on business risk.” It also notes that: “Organizations struggle to mitigate vulnerabilities because of the inability to prioritize them due to a lack of context about the assets and external threat environment.”*

This lack of visibility into active and emerging threats poses a major challenge to organizational cybersecurity, and is the primary focus of Prevailion. Through a global constellation of clandestine sensors, Prevailion actively monitors thousands of cyber attacks in real-time, including billions of malware communications, providing an unprecedented level of adversary intelligence that companies can use to protect their networks.

“We are honored to be selected by Gartner, which we believe validates the core technology behind our platform and the hard work and dedication of our team,” said Karim Hijazi, founder and CEO of Prevailion. “At Prevailion, we have been charting a new course in the field of threat intelligence, by empowering companies with greater visibility into the threat actors targeting their networks and the networks of their closest partners. By going after the attackers’ own infrastructure, we can provide companies with unprecedented insights into criminal and nation-state hackers’ malicious activity and list of targets. This enables corporate security teams to better prioritize threats, by focusing immediately on confirmed attacks, rather than having to rely on noisy and error-prone security alerts or vague risk scorecards.”

EXCLUSIVE INSIGHTS INTO CYBER THREAT ACTIVITY

Prevailion is currently tracking over 28,000 compromised organizations around the world, ranging from publicly traded companies and their supply chain partners to governments, universities, NGOs and more. Many of the cyber compromises Prevailion has observed are undetected or unreported by the victim organizations.

According to Prevailion’s exclusive intelligence, 22% of the Fortune 500 are showing active or recent compromise activity by criminal or state-affiliated hackers. This includes 79% of software companies and 64% of pharmaceuticals, which are the most heavily targeted industries, based on recent cyber activity.

Prevailion’s unique cyber intelligence capability allows it to detect active compromises inside corporate networks that do not require any access or confirmation by the affected corporation. To do this, Prevailion’s intelligence team targets criminal networks in order to intercept communications between the hackers’ “command-and-control” servers and the malware they’ve deployed. This ability to eavesdrop on criminal activity gives Prevailion significantly enhanced insights into real-time hacking operations taking place all over the world. It also allows them to anticipate new attacks ahead of time.

Prevailion’s APEX Platform is a reliable source of information on thousands of unreported corporate breaches, and provides around-the-clock intelligence on new compromises, escalating breach activity and corporate remediation efforts.

*Gartner “Cool Vendors in Security Operations and Threat Intelligence,” Mitchell Schneider, Ruggero Contu, John Watts, Craig Lawson, October 13, 2020.

GARTNER DISCLAIMER

Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

ABOUT PREVAILION

Prevailion is a compromise intelligence company, transforming the way organizations approach risk mitigation and business decision-making. Through next-level tailored intelligence and a zero-touch platform, Prevailion provides a full view of confirmed “Evidence of Compromise” (EOC) for customers and their partner ecosystems. To learn more about Prevailion, visit www.prevailion.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release

Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor

Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release

With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f

Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release

Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th

Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release

Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye